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2Abstract
• A safe, effective ambient temperature urine preservative, chlorhexidine/n-propyl gallate
(CPG), has been formulated for use during spaceflight that reduces the effects of
oxidation and bacterial contamination on sample integrity while maintaining urine pH.
The ability of this preservative to maintain stability of nine key analytes was evaluated for
a period of one year.
• CPG effectively maintained stability of ammonia, total nitrogen, 3-methylhistidine,
chloride, sodium, potassium, and urea; however, creatinine and osmolality were not
preserved by CPG.
• These data indicate that CPG offers prolonged room-temperature storage for multiple
urine analytes, reducing the requirements for frozen urine storage on future spaceflights.
Iii medical applications on Earth, this technology can allow urine samples to be collected
in remote settings and eliminate the need to ship frozen samples.
Introduction
Volume, mass, and power constraints severely limit frozen storage for biological samples
collected during spaceflight. Identifying a means of preserving urine analytes stored at ambient
temperature would lessen the impact of these limitations on biomedical research and crew health
monitoring. Several urine preservatives (e.g., boric acid, hydrochloric acid, thimerosal) are used
clinically to preserve one or more analytes. Ideally, preservatives must provide stability for
multiple analytes while minimizing hazard exposure for personnel. This is especially critical
during spaceflight. Strong acids, such as hydrochloric or acetic acid, are not available for use
during flight due to the safety hazard they pose to the crew. Additionally, strong acids tend to
alter pH, with a resultant negative effect on other analytes ( 2). Dilute solutions of boric acid
pose little risk to crewmembers, but preserve very few analytes for extended periods (3). Both
thyrnol and thimerosal have been used to preserve urine samples on Space Shuttle missions (4),
but require special handling to protect ground personnel when stock reagents are used to fill
sample tubes.
Two potential causes of analyte destruction in urine are bacterial contamination and
oxidation ( 1,5). Consequently, we designed a urine preservative that would be relatively safe for
personnel and would eliminate or reduce bacterial contamination and oxidation without altering
sample pH. The urine preservative we formulated, designated CPG, is a chemical compound
composed of equal parts of chlorhexidine gluconate and n-propyl gallate. Chlorhexidine
gluconate is a water-soluble bacteriostatic agent that is used as both a urine preservative and a
topical anti-infectant (6). The commercial food additive n-propyl gallate was chosen for its
antioxidant properties. The FDA (7,S) has deemed both chemicals safe for human use at the
4concentrations we report here. A 12-month storage study was conducted to evaluate the ability
of CPG to preserve multiple analytes in urine samples.
Materials and Methods
Materials
CPG (patent pending) was prepared in two stages. First, a 20% solution of n-propyl
gallate (Sigma Chemical Co., St. Louis, MO) was prepared by dissolving 1 gram of n-propyl
gallate in 5 mL of absolute methanol. Equal volumes of chlorhexidine gluconate (20%, Sigma
Chemical Co., St. Louis, MO) and n-propyl gallate were combined to form the working
preservative solution (CPG). Appropriate amounts of this solution were added to samples to
yield a final concentration of 0.4 mg CPG/mL urine.
Sample Collection and Preparation
Pools representing first morning voids (FMV) and 24-hour collections (24-11) were
obtained to verify analyte stability for the two most common time periods of urine collection.
Male and female volunteers (n32) collected their first urine void of the morning. These samples
were pooled and stored at 2 to 8°C while awaiting further processing (< 2 h after collection).
Five volunteers collected all urine voids for a 24-hour period in containers that were kept chilled
during collection. These five collections were then pooled and stored at 2 to 8°C until further
processing could be performed (<2 hours after completion of 24-h collection).
All samples were processed within two hours after collection was completed. Lithium
chloride, a urine volume marker used during space missions, was added to the 24-hour collection
pool. Each pool was divided into three aliquots and a sufficient quantity of CPG was added to
one aliquot to yield a final concentration of 0.4 mg CPG/mL of urine. All aliquots were further
divided into 14 replicates, one for each day of testing (days 1, 14, and 28, and monthly through 1
year), and were designated —70°C (reference storage temperature), RT (room temperature, 21 to
25°C), or CPG (room temperature with CPG). Eight analyte (e.g., sodium, potassium, ammonia)
aliquots were prepared for each of the 14 replicates, resulting in a total of 336 aliquots. On
measurement days, frozen samples were thawed and all samples were mixed well prior to
analysis.
Analytical Methods
Standard clinical laboratory methods were employed to analyze samples. Urinary sodium
and potassium were measured by ion-specific electrode techniques, chloride by silver chloride
electrode, and creatinine by the Jaffe reaction, on the Astra 4 analyzer (Beckman Instruments,
Anaheim, CA). Urinary urea nitrogen and ammonia were analyzed enzymatically on the CX5
analyzer (Beckman Instruments, Anaheim, CA). Osmolality was analyzed by freezing-point
depression technology (Fiske Associates, Norwood, MA) and 3-Methylhistidine was analyzed by
ion-exchange chromatography using the Beckman 6300 amino acid analyzer (Beckman
Instruments, Anaheim, CA). Total nitrogen was measured by pyrochemiluminescence (Antek
Instruments, Houston, TX). The accuracy and precision of each method were verified on days of
analysis by measuring samples of known concentration.
Statistical Analysis
6Performance of the —70°C stored sample was used as the reference condition to evaluate
stability. The mean and standard deviation (SD) were calculated for each analyte on data
obtained from samples stored under the reference condition. Outliers, defined here as values
outside of ± 3 SD of the mean, were removed and the acceptable range (mean ± 2 SD) was
determined for the reference condition. Precision was determined by calculating the percent
coefficient of variation (CV) for each analyte.
Stability was defined as the ability of the test condition to maintain analyte values within
the acceptable range. Two criteria were used to determine the length of analyte stability. First, if
values fell outside the ± 2 SD range for two consecutive test periods, the length of stability was
assigned to the time period when the last acceptable test result was obtained. Second, when
stability data varied between first morning void and 24-hour pools for a particular analyte, the
shorter of the two time periods was considered the cut-off point.
Regression analyses were performed to evaluate each storage condition for degradation
trends. Correlation coefficients with P values less than 0.05 were considered to demonstrate
statistically significant degradation trends. Statistical analyses were performed using Excel
(Microsoft Corp., Cambridge, MA), SAS (SAS Institute, Cary, NC), and Sigma Stat (Jandel
Scientific, Inc., San Rafael, CA) software.
Results
Outliers in the reference condition data set were identified for the following analytes:
urea 24-h day 28 (-7.1 SD), creatinine FMV day 28 (+3.3 SD), sodium FMV day 28 (+3.4 SD),
chloride FMV day 28 (+3.3 SD), and osmolality FMV day 28 (+3.2 SD). These values were
eliminated before the acceptable ranges were calculated. Resultant acceptable ranges and CVs
for the reference condition are shown in Table 1.
Deviations from the reference mean for each stable analyte are depicted in Fig. 1. In
general, analyte values obtained from the first morning void pool were the limiting factors when
determining stability. Lengths of stability for the CPG-preserved urine analytes are listed in
Table 2. Urine pH remained stable in the CPG-preserved samples (FMV: 6.42 f 0.18; 24-hr:
6.50 ± 0.24), but increased within 24 hours in the unpreserved samples (FMV: 9.04 f 1.6; 24-hr:
8.70 ± 2.0). Unpreserved urine stored at ambient temperature remained within acceptable limits
through month 7 for urea nitrogen and 2 for total nitrogen and 3-methylhistidine. Standard
deviations were within acceptable limits for sodium and potassium in unpreserved urine stored at
ambient temperature for 3 and 5 months, respectively, while chloride remained stable for only 28
days. Specimens stored unpreserved at ambient temperature yielded unacceptable standard
deviations for pH, ammonia, creatinine, and osmolality.
Regression analyses to assess degradation trends were performed on the portion of each
analyte curve that met acceptability requirements. The results are listed in Table 2. Statistically
significant degradation over time was noted for both potassium and chloride in the CPG-
preserved specimens; however, this degradation never reached the level of clinical significance
Discussion
Data from this study indicate that CPG effectively provides a safe method for ambient-
temperature storage of urine without altering pH. The length of ambient storage examined in this
study is suitable for spaceflight, although stability for 1 to 2 weeks would suffice for ground-
based analyses.
While ammonia levels remained stable for 14 days in CPG-preserved urine, the levels
increased rapidly in unpreserved samples stored at ambient temperatures. It is interesting to note
that the urea concentration in unpreserved urine decreased only slightly prior to month 8.
Previous studies have indicated that decreases in urea levels, with concurrent increases ill
ammonia concentration, would be expected to occur in the absence of a bacteriostatic agent if
urea-splitting bacteria were present in the samples (10, 11, 12). The concentration of 3-
methylhistidine decreased more rapidly in the unpreserved samples, while remaining stable for 3
months in urine samples containing CPG. These findings suggest that the breakdown of amino
acids in the urine (13) as well as some urea degradation contributed to the rapid increases in
ammonia concentration in unpreserved urine. Historically, urine samples for ammonia analysis
have been analyzed immediately, or acidified and either refrigerated or frozen to preserve sample
integrity. This study indicates that CPG is the preservative of choice for ambient-temperature
storage of urinary ammonia, urea, and 3-methylhistidine.
Urinary sodium, potassium, and chloride tended to increase over time in both the
unpreserved and CPG-preserved samples, while total nitrogen concentrations were erratic. It
remains unclear why urinary electrolytes were less stable in the unpreserved urine samples than
in CPG-preserved samples. One possible explanation is that previously bound electrolytes
became free over time, increasing more rapidly with the elevated pH levels found in the
unpreserved samples. Differences in the matrix effects of unpreserved and CPG-preserved
samples may also have contributed to the loss of stability for these analytes. Nonetheless, urine
9specimens for total nitrogen and electrolyte measurements can be safely stored at ambient
temperature for 3 and 4 months, respectively, with CPG as a preservative.
The National Committee for Clinical Laboratory Standards has established guidelines for
the development and credentialing of clinical laboratory methods (14). However, voluntary
consensus standards are not available for determining analyte stability in biological samples. The
evaluation criterion used in this study assures accuracy within clinically significant ranges (9).
CPG combines both bacteriostatic and antioxidant properties to provide a safe and
reliable method for long-term ambient-temperature storage of urine. During past Space Shuttle
and space station missions, restrictions in freezer space and power requirements have limited the
scientific data obtained during spaceflight. Furthermore, failures of the flight freezer system
have, on occasion, compromised scientific data. CPG offers the advantage of prolonged room-
temperature storage for multiple urine analytes and, therefore, may reduce the requirements for
frozen urine storage on future spaceflights. This technology can be carried over into the medical
community by allowing patients the convenience of collecting urine samples in their homes and
mailing aliquots to the physician's office or laboratory for testing. In addition, this preservative
will allow urine samples to be collected in remote settings throughout the world, where dry ice is
unavailable.
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Figure Legend
Figure 1.	 Analyte stability over time at room temperature for CPG-preserved FMV (M) and
24-h ( q ) pools. Data are expressed as ±SD from the reference mean.
Total Nitrogen
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Figure 1.
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